The role of MHC class II-restricted tumor antigens and CD4 + T cells in antitumor immunity
The identification of tumor antigens has generated a resurgence of interest in immunotherapy for cancer. However, both clinical and animal studies suggest that therapeutic strategies that have mainly focused on the use of CD8 + T cells (and MHC class I-restricted tumor antigens) are not effective in...
Gespeichert in:
Veröffentlicht in: | Trends in Immunology 2001-05, Vol.22 (5), p.269-276 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The identification of tumor antigens has generated a resurgence of interest in immunotherapy for cancer. However, both clinical and animal studies suggest that therapeutic strategies that have mainly focused on the use of CD8
+ T cells (and MHC class I-restricted tumor antigens) are not effective in eliminating cancer cells. Recent interest has been directed towards the use of CD4
+ T cells in generating antitumor immunity. To this end, the identification of MHC class II-restricted tumor antigens that can stimulate CD4
+ T cells might provide opportunities for developing effective cancer vaccines. |
---|---|
ISSN: | 1471-4906 1471-4981 |
DOI: | 10.1016/S1471-4906(01)01896-8 |